Evidence map›Paper›PMID 26022262›Full record

ReviewCNS & neurological disorders drug targets2015

The Actin Cytoskeleton as a Therapeutic Target for the Prevention of Relapse to Methamphetamine Use.

Erica J Young, Sherri B Briggs, Courtney A Miller

Abstract readReview
In one paragraph

Review in CNS & neurological disorders drug targets, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024
    Article
  6. Review
  7. Review
  8. Article
  9. Neuropsychiatric Model of Addiction Simplified.The Psychiatric clinics of North America · 2022
    Review
  10. Circadian transcription factor NPAS2 and the NADThe European journal of neuroscience · 2022
    Article
  11. Control of actin polymerizationFrontiers in cell and developmental biology · 2022
    Review
  12. Review
  13. Article
  14. Article
  15. PET Imaging of [Molecules (Basel, Switzerland) · 2020
    Article
  16. Review
  17. Methamphetamine Learning Induces Persistent and Selective Nonmuscle Myosin II-Dependent Spine Motility in the Basolateral Amygdala.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2020
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Erica J Young
Sherri B Briggs
Courtney A Miller130 Scripps Way, Jupiter, Florida 33458, USA. cmiller@scripps.edu.
Scripps Research Institute · US

Funding

Synaptic actin dynamics and the selective vulnerability of drug-associated memoryR01DA034116 · NIDA · SCRIPPS FLORIDA · PI MILLER, COURTNEY A · 2013 to 2018
$2.8M
NIDA NIH HHS R01 DA034116
6 · The paper itself

Abstract

A high rate of relapse is a defining characteristic of substance use disorder for which few treatments are available. Exposure to environmental cues associated with previous drug use can elicit relapse by causing the involuntary retrieval of deeply engrained associative memories that trigger a strong motivation to seek out drugs. Our lab is focused on identifying and disrupting mechanisms that support these powerful consolidated memories, with the goal of developing therapeutics. A particularly promising mechanism is regulation of synaptic dynamics by actin polymerization within dendritic spines. Emerging evidence indicates that memory is supported by structural and functional plasticity dendritic spines, for which actin polymerization is critical, and that prior drug use increases both spine and actin dynamics. Indeed we have found that inhibiting amygdala (AMY) actin polymerization immediately or twenty-four hours prior to testing disrupted methamphetamine (METH)-associated memories, but not food reward or fear memories. Furthermore, METH training increased AMY spine density which was reversed by actin depolymerization treatment. Actin dynamics were also shifted to a more dynamic state by METH training. While promising, actin polymerization inhibitors are not a viable therapeutic, as a multitude of peripheral process (e.g. cardiac function) rely on dynamic actin. For this reason, we have shifted our focus upstream of actin polymerization to nonmuscle myosin II. We and others have demonstrated that myosin IIb imparts a mechanical force that triggers spine actin polymerization in response to synaptic stimulation. Similar to an actin depolymerizing compound, pre-test inhibition of myosin II ATPase activity in the AMY produced a rapid and lasting disruption of drug-seeking behavior. While many questions remain, these findings indicate that myosin II represents a potential therapeutic avenue to target the actin cytoskeleton and disrupt the powerful, extinction-resistant memories capable of triggering relapse.

Indexed as

Actin CytoskeletonAnimalsBrainConditioning, OperantDendritic SpinesHumansMaleMethamphetamineNeuronal PlasticityRatsRats, Sprague-DawleyRecurrenceRewardSubstance-Related DisordersMethamphetamine

Identifiers

PMID26022262
PMCPMC4641563
OpenAlexW2126356521

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.